Abionyx Pharma P/S 2024

Abionyx Pharma Aktienanalyse

What does Abionyx Pharma do?

Abionyx Pharma SA is a biotechnology company based in France that specializes in the development and commercialization of innovative therapeutic approaches for rare diseases. The company was founded in 2000 by a group of scientists and pharmaceutical experts and has since become a leading company in the industry. The business model of Abionyx Pharma is based on the discovery and development of drugs for rare diseases. The company focuses in particular on diseases for which there are still no or only inadequate therapies. With this focus, Abionyx Pharma takes advantage of orphan drug designations and other incentive programs offered by governments and authorities around the world. These programs are intended to provide incentives for the research and development of drugs for rare diseases. Abionyx Pharma has a wide range of products in various stages of development. These include therapeutics for musculoskeletal diseases, neural disorders, and chronic inflammation. The company also has a portfolio of compounds and drugs that can be used as a platform for the development of drugs for other diseases. One of Abionyx Pharma's key products is ONO-8455, a treatment package for osteoarthritis. This is a common joint disease caused by progressive cartilage wear. ONO-8455 has the potential to be a very important therapy option for the disease and could potentially become a blockbuster drug. Another important product from Abionyx Pharma is ABX464. This is a topical therapy for the treatment of hemorrhoid inflammation. ABX464 has been tested in clinical trials and has shown promising results in terms of its effectiveness in treating hemorrhoids. Abionyx Pharma also has other projects in the pipeline, including a therapy for Fabry disease. Fabry disease is a very rare genetic disorder that affects the metabolism of lipids and other important molecules in the body. Abionyx Pharma is developing a therapy based on a novel technology that acts through DNA methylation. To achieve its business goals, Abionyx Pharma works closely with scientific and clinical partners. It also forms strategic alliances with other pharmaceutical companies to market its products globally and gain a significant market share. Overall, Abionyx Pharma is an attractive company for investors looking for a biotechnology company specializing in the development and commercialization of drugs for rare diseases. The company has a strong portfolio of products in various stages of development and has already presented promising results. With its close collaboration with partners and strategic alliances, it is able to market its products globally and remain a strong competitor in the industry. Abionyx Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Abionyx Pharma's P/S Ratio

Abionyx Pharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Abionyx Pharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Abionyx Pharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Abionyx Pharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Abionyx Pharma Stock

What is the price-to-earnings ratio of Abionyx Pharma?

The price-earnings ratio of Abionyx Pharma is currently 7.81.

How has the price-earnings ratio of Abionyx Pharma changed compared to last year?

The price-to-earnings ratio of Abionyx Pharma has increased by -3.58% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Abionyx Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Abionyx Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Abionyx Pharma affect the company?

An increase in the price-earnings ratio of Abionyx Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Abionyx Pharma affect the company?

A decrease in the price-earnings ratio of Abionyx Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Abionyx Pharma?

Some factors that influence the price-earnings ratio of Abionyx Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Abionyx Pharma pay?

Over the past 12 months, Abionyx Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abionyx Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Abionyx Pharma?

The current dividend yield of Abionyx Pharma is .

When does Abionyx Pharma pay dividends?

Abionyx Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abionyx Pharma?

Abionyx Pharma paid dividends every year for the past 0 years.

What is the dividend of Abionyx Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abionyx Pharma located?

Abionyx Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abionyx Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abionyx Pharma from 6/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.

When did Abionyx Pharma pay the last dividend?

The last dividend was paid out on 6/13/2024.

What was the dividend of Abionyx Pharma in the year 2023?

In the year 2023, Abionyx Pharma distributed 0 EUR as dividends.

In which currency does Abionyx Pharma pay out the dividend?

The dividends of Abionyx Pharma are distributed in EUR.